Saturday 17 October 2026 Export KNSA’s income statement to Excel — free account

Kiniksa Pharmaceuticals International, plc

KNSA Healthcare Drug Manufacturers Specialty & Generic

Kiniksa Pharmaceuticals International, plc’s revenue for fiscal 2025 (year ended December 2025) was $677.6 million, up 60.1% from fiscal 2024. In the quarter to June 2026, revenue grew 55.4%, EPS grew 37.5% and free cash flow grew 66.6%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for five.

78.59 1.35 −1.69%

Follow KNSA

Alert me

Market cap: $6.2B
P/E: 73.4×
Fwd P/E: 38.7×
Dividend yield: —
F-score: 8/9
Altman Z: 10.35
Beneish M: −3.16
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

	Jun '26	Mar '26	Dec '25	Sep '25	Older periods
P/E ratio Full definition →	59.77	49.13	51.56	79.24	+8 more quarters Free account
P/S ratio Full definition →	5.90	4.89	4.52	4.85
P/FCF ratio Full definition →	27.12	22.42	22.42	28.49
P/Operating CF Full definition →	105.12	73.39	56.79	86.15
P/B ratio Full definition →	7.58	6.08	5.39	5.42
Price to Tangible BV Full definition →	7.76	6.24	5.54	5.58
EV/Sales Full definition →	5.27	4.27	3.91	4.26
EV/EBITDA Full definition →	43.46	33.89	33.60	64.30
EV/Operating CF Full definition →	23.98	19.39	19.18	24.78
EV/FCF Full definition →	24.25	19.57	19.39	25.03
Quick Ratio Full definition →	3.21	3.14	3.09	3.27
Current Ratio Full definition →	3.90	3.79	3.79	3.85
Net Debt/EBITDA Full definition →	(19.01)	(15.74)	(20.46)	(14.43)
Debt/Assets Full definition →	0.00%	0.00%	0.00%	0.00%
Debt/Equity Full definition →	0.00	0.00	0.00	0.00
Asset Turnover Full definition →	1.08	1.06	1.01	0.94
Operating CF/Net income Full definition →	1.86	2.22	3.80	1.83
Capex/Depreciation Full definition →	(1.40)	(0.34)	(1.36)	(1.75)
Research and Development Expense of Revenue Full definition →	16.79%	12.82%	17.12%	13.36%
Selling, General and Administrative Expense of Revenue Full definition →	26.22%	28.54%	28.09%	27.15%
Intangible Assets out of Total Assets Full definition →	0.02	0.02	0.02	0.02
Share Based Compensation of Revenue Full definition →	4.78%	4.69%	5.06%	5.61%
Graham Net Nets Full definition →	0.09	0.10	0.11	0.10
Graham Number Full definition →	14.25	13.21	11.73	8.89
Earnings Yield Full definition →	1.67%	2.04%	1.94%	1.26%
Free Cash Flow Yield Full definition →	3.69%	4.46%	4.46%	3.51%
Revenue per Share Full definition →	3.14	2.80	2.72	2.42
Operating CF per Share Full definition →	0.61	0.66	0.73	0.45
Capex per Share Full definition →	(0.01)	0.00	(0.01)	(0.01)
Free Cash Flow per Share Full definition →	0.60	0.65	0.72	0.44
Cash per Share Full definition →	6.78	6.12	5.58	4.71
Shareholders Equity per Share Full definition →	8.43	7.92	7.65	7.17
Interest Debt per Share Full definition →	0.00	0.00	0.00	0.00
Book value per Share Full definition →	8.43	7.92	7.65	7.17
Free Cash Flow Full definition →	46.53	50.04	53.26	33.01
Working Capital Full definition →	497.39	437.56	387.99	351.94
Capital Expenditures Full definition →	(0.66)	(0.16)	(0.63)	(0.67)
Net Current Asset Value Full definition →	426.67	374.58	331.15	298.58
EV/EBIT Full definition →	44.24	34.50	34.27	66.81
Capex to Sales Full definition →	0.00	0.00	0.00	0.00
Price to Operating Income Full definition →	49.49	39.52	39.64	76.04
Other line items
Average Receivables Full definition →	27.70	31.64	28.66	38.32
Average Payables Full definition →	10.68	13.19	2.03	7.24
Average Inventory Full definition →	59.56	47.61	40.63	35.04
Average Assets Full definition →	778.63	712.30	672.09	633.82
Average Common Equity Full definition →	574.58	531.59	503.02	486.19

Show all line items

Columns are period end dates

Stockrow Weekly